Article
Dermatology
Alessandra Narcisi, Mario Valenti, Andrea Cortese, Francesco Toso, Giulia Pavia, Luigi Gargiulo, Riccardo Borroni, Antonio Costanzo
Summary: The study retrospectively compared the efficacy of anti-interleukin (IL) 23 drugs and anti-IL17 or anti-IL17RA biologics in treating scalp psoriasis, showing both types of drugs to be effective with anti-IL17 drugs achieving a faster reduction in lesions while anti-IL23 monoclonal antibodies were slightly superior in maintaining clinical improvement.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Jose Carlos Armario-Hita, Amalia Perez-Gil, Fiorella Vasquez Chinchay, Manuel Galan-Gutierrez
Summary: The IL23/Th17 axis plays a strategic role in psoriasis, and Guselkumab, a selective inhibitor of the IL23p19 subunit, has shown increased efficacy, safety, and survival in the treatment of psoriasis. This study evaluated the effectiveness, safety, and survival of Guselkumab in real clinical practice after anti-TNF alpha, anti-IL17, and/or anti-IL12/23 treatments. The results showed that Guselkumab was effective and safe, with high survival rates, even after previous biological therapy.
DERMATOLOGIC THERAPY
(2022)
Review
Immunology
Heike Schmitt, Markus F. Neurath, Raja Atreya
Summary: Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract influenced by genetic susceptibility, environmental factors, and intestinal microbiome. Pro-inflammatory cytokines IL17 and IL23 play crucial roles in the pathogenesis of CD by causing excessive activation of the mucosal immune system. Treatments targeting these cytokines, such as selective IL23 inhibitors, have shown promising results in CD patients who failed previous anti-TNF therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biology
Hanieh Kolahdooz, Vahid Khori, Vahid Erfani-Moghadam, Fatemeh Livani, Saeed Mohammadi, Ali Memarian
Summary: Psoriasis is characterized by epidermal hyperplasia and infiltration of immune cells. Poor permeation of curcumin through the skin is a major cause of medication failures. Curcumin-niosome formulations showed significant improvement in the skin lesions of psoriasis patients, with reduction in redness and scaling. Gene expression analysis indicated downregulation of IL17/IL23 immunopathogenic axis in the CUR-NIO treated group.
Article
Rheumatology
Mariagrazia Lorenzin, Augusta Ortolan, Giacomo Cozzi, Antonia Calligaro, Maria Favaro, Teresa Del Ross, Andrea Doria, Roberta Ramonda
Summary: This study evaluated potential predictors of first bDMARD failure and factors associated with failure of multiple therapies in PsA patients. It found that female patients were more likely to discontinue treatment with first bDMARD, while initiating therapy before 2015 was protective.
CLINICAL RHEUMATOLOGY
(2021)
Article
Dermatology
Matteo Megna, Luca Potestio, Angelo Ruggiero, Elisa Camela, Gabriella Fabbrocini
Summary: This real-life study evaluated the long-term efficacy and safety of guselkumab in patients who previously failed anti-IL17 treatments. The results showed significant improvement in Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) at each follow-up, as well as improvement in Nail Psoriasis Severity Index (NAPSI) after 28 weeks. Only a small percentage of patients discontinued guselkumab due to secondary inefficacy.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Review
Immunology
Matteo Vecellio, Vivien Xanath Hake, Connor Davidson, Maria Cristina Carena, B. Paul Wordsworth, Carlo Selmi
Summary: Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis, with genetic predisposition playing a key role in its development. The IL-23/IL-17 axis is highlighted as important in the immunopathogenesis of PsA.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Jie Zhang, Si-Hang Wang, Ya-Gang Zuo
Summary: This study aimed to investigate the clinical features of biologics-induced bullous pemphigoid (BP) and the therapeutic effects of those agents for BP, exploring the underlying pathophysiological mechanisms. The study found that biologics can both induce and treat BP, which might be associated with a helper T cells Th1/Th2 imbalance, complicated inflammatory networks, and a specific individual microenvironment. This finding provides a new perspective and alternative therapeutic options for BP.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Rheumatology
Burcu Yagiz, Nihal Lermi, Belkis N. Coskun, Ediz Dalkilic, Sedat Kiraz, Abdulsamet Erden, Ihsan Ertenli, Emine Duran, Emre Bilgin, Recep Yilmaz, Askin Ates, Abdurrahman Tufan, Hamit Kucuk, Ridvan Mercan, Haluk Cinakli, Servet Akar, Nazife S. Yasar Bilge, Timucin Kasifoglu, Suemeyye M. Turk, Emel Orge Gonullu, Cemal Bes, Nilufer Alpay Kanitez, Hakan Emmungil, Umut Kalyoncu, Yavuz Pehlivan
Summary: This study aims to assess the clinical characteristics, predictive factors, and practical algorithms of paradoxical reactions, specifically paradoxical psoriasis. The results show that switching to another TNFi medication is effective in treating patients with paradoxical psoriasis. Pustular and palmoplantar psoriasis are the most common types of paradoxical reactions.
Review
Immunology
Helene Bugaut, Selim Aractingi
Summary: Psoriasis is a common chronic skin inflammatory disease associated with other conditions like Crohn's disease and metabolic syndrome. IL17 and IL23 play crucial roles in psoriasis, with current treatments focusing on targeting them with monoclonal antibodies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Xiaomin Yao, Zhen Zhu, Upasana Manandhar, Han Liao, Tiexi Yu, Yueying Wang, Yawen Bian, Bo Zhang, Xuanhong Zhang, Jun Xie, Jiquan Song
Summary: This study identified the role of GNL3 in the pathogenesis of psoriasis vulgaris. GNL3 was found to regulate the IL23/IL17 axis, highlighting its potential as a target for effective treatment in the future.
Letter
Dermatology
Antonio Carriero, Ennio Lubrano, Valentina Picerno, Angela Anna Padula, Salvatore D'Angelo
Summary: Paradoxical psoriatic arthritis (PPsA) may be linked to guselkumab treatment, possibly due to cytokine imbalance.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Angelo Ruggiero, Fabrizio Martora, Vincenzo Picone, Laura Marano, Gabriella Fabbrocini, Claudio Marasca
Summary: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with unclear pathogenesis. Recent research has improved our understanding of the mechanisms behind HS lesions, including follicular occlusion and rupture, immune response activation, and imbalanced cytokine production. Paradoxical HS occurrences have been increasingly reported during treatment with biologic drugs.
Article
Dermatology
Claudio Bonifati, Aldo Morrone, Antonio Cristaudo, Dario Graceffa
Summary: New biologic drugs targeting interleukin-17 have shown quick effectiveness in treating psoriasis, but there is limited real-life data on switching to biologics targeting interleukin-23 in patients who have failed previous treatments.
DERMATOLOGIC THERAPY
(2021)
Article
Dermatology
Qianqian Zhou, Shengru Zhou, Huizi Xiong, Jianqiu Yang, Ziliang Yang, Naihui Zhou, Jinzhu Mao, Min Li
Summary: Psoriasis is an immune-mediated chronic inflammatory skin disease. While biologic agents have become increasingly important in its treatment, they can also cause paradoxical reactions as a new type of side effect.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2023)
Review
Immunology
Angelo Ruggiero, Matteo Megna, Gabriella Fabbrocini, Sonia Sofia Ocampo-Garza
IMMUNOLOGIC RESEARCH
(2023)
Review
Pathology
Daniela Russo, Rossella Accarino, Silvia Varricchio, Raduan Ahmed Franca, Luca Potestio, Cataldo Patruno, Maddalena Napolitano, Massimo Mascolo
Summary: During the Cov-19 pandemic, various cutaneous reactions have been observed in relation to Cov-19 infection and SARS-CoV-2 vaccination. This study highlights a case of granuloma annulare (GA) developing after SARS-CoV-2 vaccination and reviews previous cases of GA associated with vaccination and infection.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Article
Medicine, General & Internal
Fabrizio Martora, Claudio Marasca, Vincenzo Picone, Luigi Fornaro, Matteo Megna, Gabriella Fabbrocini
Summary: We conducted a one-year prospective study involving 58 patients with Hidradenitis Suppurativa. By retrospectively analyzing data and comparing it to the year before starting adalimumab, an anti-TNF alpha drug, we aimed to assess how this biologic therapy affects antibiotic therapy, flare-ups frequency and duration, as well as patients' quality of life and perceived pain.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Dermatology
Matteo Megna, Mario De Lucia, Lucia Gallo, Wanda Lauro, Vincenzo Picone, Gabriella Fabbrocini, Sonia Sofia Ocampo-Garza
Summary: This case report describes a patient with psoriatic alopecia and paradoxical psoriasis induced by adalimumab, who successfully switched to certolizumab and achieved a good treatment response. Certolizumab is shown to be an effective and safe alternative therapeutic option for managing psoriasis and psoriatic arthritis, minimizing the risk of paradoxical reactions.
SKIN APPENDAGE DISORDERS
(2023)
Letter
Dermatology
Fabrizio Martora, Angelo Ruggiero, Teresa Battista, Luca Potestio, Matteo Megna
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2023)
Letter
Dermatology
Luca Potestio, Angelo Ruggiero, Gabriella Fabbrocini, Fabrizio Martora, Luca Costanzo, Lucia Gallo
Summary: Current guidelines recommend oral ivermectin as the first-line treatment, with a dose of 200 μg/kg taken in two doses 1-week apart (to be taken with food). However, the recently approved ivermectin formulation in Italy suggests a single dose. In response to this, we conducted a retrospective analysis at our Dermatological Clinic of Mycology and Parasitosis and present our findings, following a similar study conducted by Balestri et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2023)
Letter
Dermatology
Fabrizio Martora, Teresa Battista, Luca Potestio, Massimiliano Scalvenzi, Paola Nappa, Matteo Megna
Summary: This comment discusses the onset of epidermolysis bullosa acquisita during therapy with ustekinumab for the treatment of Crohn disease.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2023)
Editorial Material
Allergy
Luca Potestio, Maddalena Napolitano, Francesca Di Vico, Gabriella Fabbrocini, Cataldo Patruno
CONTACT DERMATITIS
(2023)
Article
Biotechnology & Applied Microbiology
Giacomo Caldarola, A. Chiricozzi, M. Megna, P. Dapavo, A. Giunta, M. Burlando, P. Malagoli, V Dini, M. Mariani, G. Fabbrocini, P. Quaglino, L. Bianchi, A. Parodi, K. Peris, C. De Simone
Summary: This study aimed to evaluate the 3-year drug survival of ixekizumab in the treatment of moderate-to-severe plaque psoriasis patients. It found that ixekizumab is characterized by long-term effectiveness and good safety profile, not influenced by several clinical factors.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Article
Pharmacology & Pharmacy
Alessia Villani, Massimiliano Scalvenzi, Giuseppe Micali, Francesco Lacarrubba, Lucia Genco, Angelo Ruggiero, Luigi Fornaro, Gianluca Guerrasio, Luca Potestio
Summary: Surgery is the standard treatment for most basal cell carcinomas (BCC), but in some cases, radiotherapy, ablative and topical treatments may also be valuable options. Locally advanced BCCs (laBCC) and metastatic BCC, also referred to as 'difficult-to-treat' BCC, pose a challenge for current treatment approaches. The development of new selective therapies targeting the Hedgehog (HH) pathway, such as sonidegib, has shown promising results in managing difficult-to-treat BCC.
EXPERT OPINION ON DRUG SAFETY
(2023)
Review
Medicine, General & Internal
Giuseppina Caiazzo, Anna Caiazzo, Maddalena Napolitano, Matteo Megna, Luca Potestio, Luigi Fornaro, Melania Parisi, Maria Antonietta Luciano, Angelo Ruggiero, Anna Testa, Fabiana Castiglione, Cataldo Patruno, Maria Quaranta, Gabriella Fabbrocini
Summary: The JAK/STAT pathway plays a critical role in immune and inflammatory responses, as well as various cellular processes. Its involvement in the pathogeneses of chronic inflammatory conditions like psoriasis, atopic dermatitis, and inflammatory bowel diseases has been extensively studied. However, the exact impact of this pathway on the pathogenesis of inflammatory conditions remains unclear.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Dermatology
Angelo Ruggiero, Gabriella Fabbrocicni, Sara Cacciapuoti, Luca Potestio, Lucia Gallo, Matteo Megna
Summary: Background: Tildrakizumab has shown promising efficacy and safety in clinical trials, but real-life data are limited. Objective: To assess the efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis. Results: The study showed significant reduction in PASI score and high rates of PASI90 and PASI100 responses, with few reported adverse events, up to 52 weeks of follow-up. Treatment also improved patients' quality of life.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2023)
Article
Dermatology
Matteo Megna, Teresa Battista, Matteo Noto, Vincenzo Picone, Gabriella Fabbrocini, Angelo Ruggiero, Lucia Genco
Summary: This study found that a considerable proportion of psoriasis patients who received biologic treatment experienced injection site reactions (ISRs) such as swelling, pain, burning, and erythema, which could affect patient adherence. The incidence of these symptoms varied among different classes of biologics, with Ixekizumab showing the highest rates. However, these ISRs did not lead to discontinuation or delay of treatment.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2023)
Review
Dermatology
Luca Potestio, Angelo Ruggiero, Gabriella Fabbrocini, Fabrizio Martora, Matteo Megna
Summary: Psoriasis management is challenging, particularly for moderate-to-severe cases where conventional systemic treatments and phototherapy have limitations. Despite the development of biological drugs and small molecules, there is still a need for new therapies to tailor treatment and maintain long-term effectiveness. Deucravacitinib, an oral small molecule inhibiting Tyrosine Kinase 2, shows promise in psoriasis management. This review aims to evaluate the efficacy and safety of deucravacitinib for psoriasis management.
PSORIASIS-TARGETS AND THERAPY
(2023)
Article
Medicine, General & Internal
Matteo Megna, Angelo Ruggiero, Teresa Battista, Laura Marano, Sara Cacciapuoti, Luca Potestio
Summary: This study investigated the long-term efficacy and safety of risankizumab for the management of moderate to severe psoriasis. The results showed significant reduction in psoriasis severity scores from week 16 and maintained up to week 104, with no serious adverse events reported.
JOURNAL OF CLINICAL MEDICINE
(2023)